Zevra Therapeutics Management
Management criteria checks 0/4
Zevra Therapeutics' CEO is Neil McFarlane, appointed in Oct 2023, has a tenure of 1.58 years. total yearly compensation is $5.36M, comprised of 13.1% salary and 86.9% bonuses, including company stock and options. directly owns 0.35% of the company’s shares, worth $1.66M. The average tenure of the management team and the board of directors is 1.6 years and 2.1 years respectively.
Key information
Neil McFarlane
Chief executive officer
US$5.4m
Total compensation
| CEO salary percentage | 13.07% |
| CEO tenure | 1.6yrs |
| CEO ownership | 0.4% |
| Management average tenure | 1.6yrs |
| Board average tenure | 2.1yrs |
Recent management updates
Recent updates
Revenues Tell The Story For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) As Its Stock Soars 26%
May 22
MIPLYFFA Launch Will Spark European Expansion In 2025
Successful MIPLYFFA launch and European expansion plans indicate potential revenue growth and stable streams through strong demand and patient engagement.Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects
Mar 10Here's What Analysts Are Forecasting For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) After Its Third-Quarter Results
Nov 15Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects As Shares Rocket 34%
Aug 30Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) 26% Jump Shows Its Popularity With Investors
Jul 12Analysts Just Shaved Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Forecasts Dramatically
Apr 07Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Just Reported And Analysts Have Been Cutting Their Estimates
Apr 04Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Stock Retreats 27% But Revenues Haven't Escaped The Attention Of Investors
Apr 02Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects
Dec 28Bullish: Analysts Just Made A Noticeable Upgrade To Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Forecasts
Sep 05This Just In: Analysts Are Boosting Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Outlook for This Year
Aug 20Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Stocks Shoot Up 31% But Its P/S Still Looks Reasonable
Apr 17US$18.00: That's What Analysts Think Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Is Worth After Its Latest Results
Mar 10Is Zevra Therapeutics (NASDAQ:ZVRA) Using Debt In A Risky Way?
Mar 08Bearish: Analysts Just Cut Their KemPharm, Inc. (NASDAQ:KMPH) Revenue and EPS estimates
Nov 16CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | -US$92m |
| Dec 31 2024 | US$5m | US$700k | -US$106m |
| Sep 30 2024 | n/a | n/a | -US$90m |
| Jun 30 2024 | n/a | n/a | -US$67m |
| Mar 31 2024 | n/a | n/a | -US$49m |
| Dec 31 2023 | US$3m | US$158k | -US$46m |
Compensation vs Market: Neil's total compensation ($USD5.36M) is above average for companies of similar size in the US market ($USD2.64M).
Compensation vs Earnings: Neil's compensation has increased whilst the company is unprofitable.
CEO
Neil McFarlane (51 yo)
Mr. Neil F. McFarlane serves as President & Chief Executive Officer at Zevra Therapeutics, Inc. since October 10, 2023 and serves as its Director since October 9, 2023. He served as Independent Director at...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1.6yrs | US$5.36m | 0.35% $ 1.7m | |
| CFO & Treasurer | 9.9yrs | US$1.45m | 0.094% $ 444.8k | |
| Chief Medical Officer | 1.3yrs | US$2.52m | 0.0053% $ 25.3k | |
| Vice President of Investor Relations & Corporate Communications | 2.8yrs | no data | no data | |
| Chief Legal Officer | less than a year | no data | no data | |
| Chief People Officer | less than a year | no data | no data | |
| Senior Vice President of Manufacturing | 2.3yrs | no data | no data | |
| Chief Commercial Officer | 2.3yrs | US$1.82m | 0.054% $ 255.4k | |
| Senior Vice President of Regulatory Affairs & Quality | 1.3yrs | no data | no data | |
| Senior VP & Chief of Staff | 1.3yrs | no data | no data | |
| Senior VP & Corporate Controller | 8.3yrs | no data | 0.030% $ 141.5k |
Experienced Management: ZVRA's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1.6yrs | US$5.36m | 0.35% $ 1.7m | |
| Independent Director | 2.1yrs | US$231.01k | 0% $ 0 | |
| Independent Director | 2.1yrs | US$228.16k | 0% $ 0 | |
| Independent Chair | 3.8yrs | US$364.97k | 0.0013% $ 6.2k | |
| Member of Scientific and Medical Advisory Board | no data | no data | no data | |
| Independent Director | 2.1yrs | US$241.94k | 0.073% $ 346.4k | |
| Independent Director | 2.1yrs | US$236.44k | 0.0033% $ 15.6k | |
| Chairman of Scientific and Medical Advisory Board | 18.3yrs | no data | no data | |
| Member of Scientific & Medical Advisory Board | no data | no data | no data | |
| Co-Chair of Physician Advisory Council | 11.6yrs | no data | no data | |
| Co-Chair of Physician Advisory Council | 11.6yrs | no data | no data | |
| Independent Director | 1.8yrs | US$237.59k | 0.037% $ 173.2k |
Experienced Board: ZVRA's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/22 06:10 |
| End of Day Share Price | 2025/05/22 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Zevra Therapeutics, Inc. is covered by 16 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sumant Satchidanand Kulkarni | Canaccord Genuity |
| Dewey Steadman | Canaccord Genuity |
| Kristen Kluska | Cantor Fitzgerald & Co. |